Which antiretroviral (HIV) medications can cause clinically significant acid‑base disturbances, and how should these disturbances be monitored and managed?

Acid-Base Disturbances from HIV Medications

Nucleoside reverse transcriptase inhibitors (NRTIs), particularly stavudine and didanosine, are the primary antiretroviral medications that cause clinically significant lactic acidosis—a rare but potentially fatal acid-base disturbance with a mortality rate approaching 50%. 1

Medications That Cause Lactic Acidosis

High-Risk NRTIs (Avoid if Possible)

• Stavudine (d4T) and didanosine (ddI): These are the most notorious culprits, accounting for 76% of reported lactic acidosis cases 2
• Zidovudine (AZT): Also associated with mitochondrial toxicity
• The combination of didanosine + ribavirin is absolutely contraindicated due to severe lactic acidosis, steatosis, and pancreatitis risk 3

Lower-Risk NRTIs (Currently Used)

• Abacavir and tenofovir: Have largely replaced the older NRTIs, resulting in decreased incidence of lactic acidosis in clinical practice 4
• Modern regimens using these agents carry substantially lower risk

Mechanism

NRTIs inhibit mitochondrial DNA polymerase γ, causing mitochondrial dysfunction that leads to lactic acidosis with hepatic steatosis 1. This same mechanism can cause pancreatitis, peripheral neuropathy, myopathy, and cardiomyopathy.

Risk Factors for Development

Female sex is the strongest predictor (OR 7.19), followed by:

• Obesity/elevated BMI 1, 5
• Prolonged NRTI use
• Pregnancy (especially late-stage or postpartum) 1
• Combination of stavudine + didanosine with other antiretrovirals 1

Notably, efavirenz (an NNRTI) was independently associated with increased risk of symptomatic hyperlactatemia (OR 2.18) in one large randomized trial—a novel finding 5.

Clinical Recognition

Symptoms to Monitor

The presentation is often nonspecific and insidious 1:

• Abdominal distention, nausea, vomiting, abdominal pain, diarrhea
• Anorexia and weight loss
• Dyspnea and generalized weakness
• Ascending neuromuscular weakness, myalgias, paresthesias
• Hepatomegaly

Critical pitfall: Symptoms can occur without substantial hepatic enzyme elevation initially 1.

Laboratory Monitoring Strategy

Do NOT routinely monitor lactate levels due to substantial technical problems with testing 1. Instead:

1. Every 3 months, monitor:

   • Serum bicarbonate
   • Electrolytes (calculate anion gap: Na − [Cl + CO₂])
   • Anion gap >16 suggests developing acidosis 1

2. When symptoms develop, check:

   • Venous lactate (if abnormal, repeat with arterial blood gas)
   • Aminotransferases, CPK, LDH, lipase, amylase
   • Imaging (ultrasound/CT) may show fatty liver 1

Lactate Interpretation (When Measured)

Lactate must be collected properly: prechilled fluoride-oxalate tubes, transported on ice immediately, processed within 4 hours, collected without tourniquet or fist-clenching 1:

• 2-5 mmol/L: Elevated—correlate with symptoms, close monitoring required
• >5 mmol/L: Abnormal—intervention needed
• >10 mmol/L: Life-threatening—immediate action required 1

Management Algorithm

For Symptomatic Hyperlactatemia (Lactate 2-5 mmol/L)

1. Increase monitoring frequency
2. Educate patient about worsening symptoms
3. Consider switching to NRTI-sparing regimen or safer NRTIs (abacavir, tenofovir)

For Lactic Acidosis (Lactate >5 mmol/L or pH <7.35)

Immediately discontinue all antiretroviral therapy 1:

1. Intensive supportive care:

   • Bicarbonate infusions (AI evidence rating) 1
   • Hemodialysis if severe (AI evidence rating) 1
   • Mechanical ventilation if respiratory failure develops

2. Adjunctive therapy (pathophysiologic rationale, but unproven efficacy):

   • Thiamine 1
   • Riboflavin 1

3. After resolution:

   • Some patients tolerate reintroduction of different NRTI-containing regimens 1
   • However, NRTI-sparing regimens are safer given insufficient data on rechallenge 1
   • Modern options include integrase inhibitor-based regimens without problematic NRTIs

Prevention Strategy

The most effective prevention is avoiding high-risk NRTIs entirely 4:

• Use modern first-line regimens: integrase inhibitor + tenofovir/emtricitabine or abacavir/lamivudine 6, 7
• Consider two-drug regimens (dolutegravir/lamivudine) when appropriate 6, 7
• Never combine didanosine with ribavirin 3
• Switch patients on stavudine or didanosine to safer alternatives

Patient Education

Educate all patients starting NRTIs about symptoms of lactic acidosis and instruct them to report promptly 4. Early recognition with symptom-based surveillance is more practical than routine lactate monitoring.

Other Acid-Base Considerations

Tenofovir can cause proximal renal tubular acidosis (type 2 RTA) with Fanconi syndrome, presenting as non-anion gap metabolic acidosis 8. This is distinct from lactic acidosis and requires monitoring renal function, particularly when combined with boosting agents or in patients with baseline renal impairment 3.